Journal of Diabetes Investigation (Dec 2022)
Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis
Abstract
Abstract Aims/Introduction The etiology and treatment of type 2 diabetes might differ between specific populations. This post‐hoc exploratory analysis assessed the efficacy and safety of once‐weekly subcutaneous semaglutide vs comparators in Japanese individuals with type 2 diabetes in comparison with the total population from four phase III studies in the Trial to Evaluate Cardiovascular and Other Long‐term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN) program. Materials and Methods This analysis was carried out with data from the SUSTAIN 1, 2, 5 and 9 trials. Post‐hoc analyses were carried out to assess outcomes in all participants and in Japanese participants in each study. The primary end‐point was the change from baseline to end of study in glycated hemoglobin (%). The confirmatory secondary end‐point was change from baseline to end of study in bodyweight (kg). Results Change from baseline to end of study in glycated hemoglobin with once‐weekly semaglutide ranged from −1.32 to −1.85% points in the overall populations, and −1.69 to −2.49% points in Japanese participants. With once‐weekly semaglutide, relative bodyweight was reduced from baseline to end of study by 4.0–7.3% in the overall populations, and 2.7–10.4% in Japanese participants. In the Japanese subpopulation, no new safety concerns were identified with once‐weekly semaglutide, and there were no adverse events leading to death or severe hypoglycemic episodes. Conclusions In this post‐hoc analysis, participants with type 2 diabetes initiating once‐weekly semaglutide experienced improvements in glycated hemoglobin and bodyweight in both the overall and Japanese population, and no new safety concerns were identified among Japanese participants, supporting the efficacy of once‐weekly semaglutide in this population.
Keywords
